417 related articles for article (PubMed ID: 34766650)
1. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
[TBL] [Abstract][Full Text] [Related]
2. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
4. Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):1017-1019. PubMed ID: 35179767
[TBL] [Abstract][Full Text] [Related]
5. Serum and tissue metallome of pancreatic ductal adenocarcinoma.
Byeon S; du Toit-Thompson T; Hipperson L; Maloney S; Wenzel R; Gill AJ; Samra JS; Mittal A; Sahni S
Cancer Sci; 2024 May; 115(5):1446-1458. PubMed ID: 38438247
[TBL] [Abstract][Full Text] [Related]
6. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
7. The detection of tumor location and lymph node metastasis by aberrant NXPH1 and NXPH2 expressions in pancreatic ductal adenocarcinomas.
Jin JS; Tsai WC
Chin J Physiol; 2016 Dec; 59(6):348-354. PubMed ID: 27817196
[TBL] [Abstract][Full Text] [Related]
8. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
[TBL] [Abstract][Full Text] [Related]
9. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
10. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
Iakovlev V; Siegel ER; Tsao MS; Haun RS
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
[TBL] [Abstract][Full Text] [Related]
11. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
12. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
13. The biology of pancreatic cancer morphology.
McDonald OG
Pathology; 2022 Mar; 54(2):236-247. PubMed ID: 34872751
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
Urayama S
World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
[TBL] [Abstract][Full Text] [Related]
16. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
18. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
19. Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes.
Massoumi RL; Hines OJ; Eibl G; King JC
Pancreas; 2019 Jan; 48(1):1-8. PubMed ID: 30531240
[TBL] [Abstract][Full Text] [Related]
20. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
Tesfaye AA; Azmi AS; Philip PA
Am J Pathol; 2019 Jan; 189(1):58-70. PubMed ID: 30558723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]